title: A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
abstract: BACKGROUND
  The outcome of stage III gastric cancer patients treated by D2 dissection followed by adjuvant chemotherapy with S-1 remains unsatisfactory. Moreover, some patients with a preoperative diagnosis of stage II/III turn out to be stage IV after surgical exploration, and a standard postoperative treatment for this population has not been established.
  
  
  METHODS
  A feasibility study of postoperative S-1/cisplatin (CDDP) was performed with patients who underwent gastrectomy for what turned out to be a stage IV gastric cancer. The primary endpoint of the trial was the relative dose intensity during five courses of S-1/CDDP. Several criteria to skip, postpone, or reduce the dose had been predetermined.
  
  
  RESULTS
  Between 2007 and 2009, 31 patients were accrued, including 19 patients who were positive for peritoneal washing cytology, 6 with peritoneal seeding, 5 with metastasis to the paraaortic nodes, and 4 with other distant metastases. Only 7 patients completed five cycles as planned (median, two cycles). The median relative dose intensities of S-1 and CDDP were 37% and 40%, respectively. Causes of treatment failure were failure to fulfill criteria for starting a new course within 5 weeks of the last administration of S-1 in 7, patient refusal in 6, disease recurrence/progression in 4, need to reduce dose by two levels in 4, and two successive skips of CDDP in 3 patients. The median progression-free survival time of all patients was 363 days.
  
  
  CONCLUSIONS
  Although promising in the neoadjuvant and advanced/metastatic setting, S-1/CDDP is too toxic as a postgastrectomy treatment for Japanese patients.
authors.affiliation: Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kodera
authors.forename: Akiharu
authors.initials: A
authors.lastname: Ishiyama
authors.forename: Takaki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Kinoshita
authors.forename: Seiji
authors.initials: S
authors.lastname: Ito
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Mochizuki
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ito
authors.forename: Akira
authors.initials: A
authors.lastname: Tsuburaya
authors.forename: Junichi
authors.initials: J
authors.lastname: Sakamoto
authors.forename: Akimasa
authors.initials: A
authors.lastname: Nakao
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011182:Postoperative Care; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin
references.citation: Gastric Cancer. 2004;7(2):104-9
references.pmid: 15224197
references.citation: Ann Oncol. 2010 May;21(5):1001-5
references.pmid: 19875759
references.citation: Gastric Cancer. 2008;11(4):192-3
references.pmid: 19132479
references.citation: Gastric Cancer. 1998 Dec;1(1):25-30
references.pmid: 11957041
references.citation: Eur J Cancer. 1998 Oct;34(11):1715-20
references.pmid: 9893658
references.citation: Ann Oncol. 2005 Sep;16(9):1488-97
references.pmid: 15939717
references.citation: Oncology. 2008;74(1-2):37-41
references.pmid: 18544958
references.citation: Gastric Cancer. 2006;9(2):51-66
references.pmid: 16767357
references.citation: N Engl J Med. 2008 Jan 3;358(1):36-46
references.pmid: 18172173
references.citation: Eur J Surg Oncol. 2009 Nov;35(11):1158-63
references.pmid: 19328643
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: Gastric Cancer. 2007;10(1):29-34
references.pmid: 17334715
references.citation: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7
references.pmid: 16740764
references.citation: Gastric Cancer. 2006;9(2):129-35
references.pmid: 16767369
references.citation: Oncology. 2000 Apr;58(3):191-7
references.pmid: 10765119
references.citation: N Engl J Med. 2007 Nov 1;357(18):1810-20
references.pmid: 17978289
references.citation: Int J Cancer. 1999 Sep 24;83(1):18-29
references.pmid: 10449602
references.citation: Gastric Cancer. 2007;10(2):129-34
references.pmid: 17577624
references.citation: Jpn J Clin Oncol. 2008 Jul;38(7):504-6
references.pmid: 18617536
references.citation: Am J Surg. 2004 Mar;187(3):440-5
references.pmid: 15006580
references.citation: J Cancer Res Clin Oncol. 2006 Dec;132(12):781-5
references.pmid: 16804723
references.citation: Br J Cancer. 2003 Dec 15;89(12):2207-12
references.pmid: 14676796
references.citation: N Engl J Med. 2001 Sep 6;345(10):725-30
references.pmid: 11547741
references.citation: Lancet Oncol. 2008 Mar;9(3):215-21
references.pmid: 18282805
references.citation: Oncology. 2007;73(1-2):65-71
references.pmid: 18334851